Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Technology appraisal guidance
Reference number: TA569
Published:
The company has updated their commercial offer for pertuzumab for adjuvant treatment of early HER2-positive breast cancer. The new offer will be considered in a closed session at the committee meeting on 8 January 2019.